Sponsorship reflects commitment to increasing access to care for orthodontic treatment especially for children, and Align’s support of the Canadian orthodontic profession TEMPE, Ariz.–(BUSINESS WIRE)–Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital … [Read more…]

ZHUZHOU, China & BOSTON–(BUSINESS WIRE)–Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for … [Read more…]

Two peptide programs validate the AnimateIQ™ platform with strong anti-fibrotic efficacy, improved systemic health and broad biological relevance SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung fibrosis and inflammation. Notably, the company’s lead peptide performed comparably … [Read more…]

Dr. Taz MD, The Pioneer of Doctor-led Evidence Based Holistic Medicine, transforms her 20+ years of experience into a comprehensive holistic health hub for the whole family ATLANTA–(BUSINESS WIRE)–#functionalmedicine—Dr. Taz Bhatia, a leading expert in modernized holistic medicine, integrating traditional healing with contemporary medical advancements, has reimagined the future of health with the launch of … [Read more…]

First phase 3 trial to prospectively enroll patients with tumors that test positively for TROP2 NMR, a novel computational pathology biomarker to identify those most likely to benefit from Daiichi Sankyo and AstraZeneca’s DATROWAY TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) … [Read more…]

BARCELONA & DEERFIELD, Ill.–(BUSINESS WIRE)–ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire TerSera’s Infusion Specialty Therapies Business Unit (IST). This strategic acquisition enables ESTEVE to expand its U.S. presence, with two highly specialized on-market assets and a dedicated team of sales, marketing and medical … [Read more…]

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant … [Read more…]

120M+ cells and 225,000 perturbation interactions will accelerate virtual cell model development in a first-of-its-kind partnership and will be released open source as part of a shared commitment to open science. SAN FRANCISCO & PALO ALTO, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tahoe Therapeutics, Arc Institute, and Biohub announced a landmark initiative to generate the largest … [Read more…]

AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera’s multimodal AI foundation model platform and expand applications across precision medicine. Under the collaboration, Natera will integrate its unique longitudinal and multi-time point in vivo datasets and … [Read more…]

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026 PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study with initial data from multiple patients expected in 2026 Unaudited cash, cash equivalents, and restricted cash of approximately $137 million as of December 31, … [Read more…]